Company to Host Conference Call and Webcast
on August 7, 2024
LOS
ANGELES, July 31, 2024 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision
oncology company focused on developing and commercializing
therapies for cancers with alterations in the mTOR pathway, today
announced that it will host a conference call and live webcast
on Wednesday, August 7, 2024, at 8:30 am
EDT (5:30 am PDT) to report
second quarter 2024 financial results and provide recent corporate
updates.
Conference Call Information
Participants may access a
live webcast of the call on the "Investors & News" page of
the Aadi Bioscience website at aadibio.com. To
participate via telephone, please register in advance here:
Conference Registration (vevent.com). Upon registration, all
telephone participants will receive a confirmation email detailing
how to join the conference call, including the dial-in number along
with a unique passcode and registrant ID that can be used to access
the call. A replay of the conference call and webcast will be
archived on the website for at least 30 days.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage
precision oncology company focused on the development and
commercialization of therapies for cancers with alterations in the
mTOR pathway, a key regulator of cell growth and cancer
progression. To unlock the full potential of mTOR inhibition, Aadi
uniquely combines nanoparticle albumin-bound (nab)
technology with the potent mTOR inhibitor, sirolimus. Aadi received
FDA approval and commercializes FYARRO® for the treatment of adult
patients with locally advanced unresectable or metastatic malignant
perivascular epithelioid cell tumor (PEComa).
Aadi is exploring nab-sirolimus in PRECISION1, a
Phase 2 tumor-agnostic registration-intended trial in mTOR
inhibitor-naïve malignant solid tumors
harboring TSC1 or TSC2 inactivating
alterations. Aadi is also exploring nab-sirolimus in
two single-indication Phase 2 trials for difficult-to-treat
mTOR-driven cancers: neuroendocrine tumors (NETs) of the lung,
gastrointestinal tract and pancreas, and advanced or recurrent
endometrioid-type endometrial cancer (EEC) in combination with
letrozole. More information on Aadi's development pipeline is
available on the Aadi website at www.aadibio.com and
connect with us on Twitter and LinkedIn.
Contact:
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-second-quarter-2024-results-and-corporate-update-302211486.html
SOURCE Aadi Bioscience